Compare Heron Therapeutics Inc (HRTX) vs SS&C Technologies Holdings Inc. Common Stock (SSNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs SS&C Technologies Holdings Inc. Common Stock — how do they compare? Heron Therapeutics Inc trades at $0.36 (market cap $74.18M), while SS&C Technologies Holdings Inc. Common Stock trades at $82.08 (market cap $19.13B). The key difference: SS&C Technologies Holdings Inc. Common Stock is far larger — about 257.9× Heron Therapeutics Inc's market cap, and SS&C Technologies Holdings Inc. Common Stock pays a 1.47% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 36 Days and SS&C Technologies Holdings Inc. Common Stock for 0 Days on average.
| HRTX | SSNC | |
|---|---|---|
Market Cap | $74.18M | $19.13B |
Volume | 1,857,401 | 1,333,448 |
Sector | Health | Technology |
52-Week High | $1.49 | $89.62 |
52-Week Low | $0.27 | $62.05 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $180.92M | $26.47B |
Dividend Yield | — | 1.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3906, down 6.02% today, with a bullish technical signal from moving averages and oscillators. The company reported Q2 2026 revenue of $37.7 million but missed EPS estimates. Despite a high gross margin of 70.07%, it posted a net loss of -$20.20 million in 2025. Analyst consensus is strongly positive with 17 buy ratings. Recent news highlights earnings results and competitive comparisons.
The outlook remains speculative given persistent losses and negative ROE, but strong analyst support and improving cash flow trends offer potential upside. Key risks include profitability challenges and revenue volatility. Investors should weigh the bullish sentiment against fundamental weaknesses.
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About SS&C Technologies Holdings Inc. Common Stock
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →
